WO2024110853 - SOLID FORMS OF A FUSED PYRIDINE FOR THE TREAMTENT OF CANCER
National phase entry:
Publication Number
WO/2024/110853
Publication Date
30.05.2024
International Application No.
PCT/IB2023/061715
International Filing Date
21.11.2023
Title **
[English]
SOLID FORMS OF A FUSED PYRIDINE FOR THE TREAMTENT OF CANCER
[French]
FORMES SOLIDES D'UNE PYRIDINE FUSIONNÉE POUR LE TRAITEMENT DU CANCER
Applicants **
NOVARTIS AG
Inventors
BRUN, Jvan
HAMON, Jacques
HINRICHS, Juergen Hans-Hermann
HONG, Ziyue
MOEBITZ, Henrik
PERLBERG, Anett
SCHOEPFER, Joseph
STRANG, Ross
WANG, Chang
Priority Data
PCT/CN2022/133692
23.11.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2311 | |
| EPO | Filing, Examination, Granting | 12395 | |
| Japan | Filing, Examination, Granting | 2400 | |
| South Korea | Filing, Examination, Granting | 2568 | |
| USA | Filing, Examination, Granting | 14940 |
Total:
34,614
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to solid forms of Compound (A), and a pharmaceutical composition comprising said solid form. The solid form of Compound (A) of the present invention, or the pharmaceutical composition of the present invention, can be used as a medicament.[French]
La présente invention concerne des formes solides du composé (A), et une composition pharmaceutique comprenant ladite forme solide. La forme solide du composé (A) de la présente invention, ou la composition pharmaceutique de la présente invention, peut être utilisée en tant que médicament.